Harvard Bioscience, Inc. - Common Stock (HBIO)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- P/B of 15.86 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -427.1%
- Revenue declining 8% annually
Harvard Bioscience, Inc. - Common Stock (HBIO) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $218 million . Key value metrics: P/B ratio 15.86, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Harvard Bioscience, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, HBIO shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -427.1% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 2.61.
StockPik's composite Value Score for HBIO is 27/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HBIO reports a solid gross margin of 57.2% (sector average: 33.5%) and a negative operating margin of -61.5%.
HBIO shows revenue declining at 8% year-over-year, with earnings declining at 357%.